Cargando…

Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease

BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Sha, Liu, Hui-Hui, Guo, Yuan-Lin, Zhu, Cheng-Gang, Wu, Na-Qiong, Xu, Rui-Xia, Dong, Qian, Qian, Jie, Dou, Ke-Fei, Li, Jian-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096217/
https://www.ncbi.nlm.nih.gov/pubmed/35574011
http://dx.doi.org/10.3389/fendo.2022.860698
_version_ 1784705925503778816
author Li, Sha
Liu, Hui-Hui
Guo, Yuan-Lin
Zhu, Cheng-Gang
Wu, Na-Qiong
Xu, Rui-Xia
Dong, Qian
Qian, Jie
Dou, Ke-Fei
Li, Jian-Jun
author_facet Li, Sha
Liu, Hui-Hui
Guo, Yuan-Lin
Zhu, Cheng-Gang
Wu, Na-Qiong
Xu, Rui-Xia
Dong, Qian
Qian, Jie
Dou, Ke-Fei
Li, Jian-Jun
author_sort Li, Sha
collection PubMed
description BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944 patients with ASCVD was recruited. Recurrent events occurred during an average of 38.5 months’ follow-up were collected. The respective and combinative roles of major ASCVD (mASCVD) events and high-risk conditions, being defined by 2018 AHA/ACC guideline, in coronary severity and outcome were studied. RESULTS: The number of high-risk conditions was increased with increasing number of mASCVD events (1.95 ± 1.08 vs. 2.16 ± 1.10 vs. 2.42 ± 1.22). Trends toward the higher to the highest frequency of multi-vessel coronary lesions were found in patients with 1- (71.1%) or ≥2 mASCVD events (82.8%) when compared to those without (67.9%) and in patients with 2- (70.5%) or ≥3 high-risk conditions (77.4%) when compared to those with 0-1 high-risk condition (61.9%). The survival rate was decreased by 6.2% between none- and ≥2 mASCVD events or by 3.5% between 0-1 and ≥3 high-risk conditions. Interestingly, diabetes was independently associated with outcome in patients with 1- [1.54(1.06-2.24)] and ≥2 mASCVD events [1.71(1.03-2.84)]. The positive predictive values were increased among groups with number of mASCVD event increasing (1.10 vs. 1.54 vs. 1.71). CONCLUSION: Propitious refinement of ASCVD might be reasonable to improve the survival. Concomitant diabetes was differently associated with the incremental risk among different ASCVD categories, suggesting the need of an appropriate estimate rather than a ‘blanket’ approach in risk stratification.
format Online
Article
Text
id pubmed-9096217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90962172022-05-13 Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease Li, Sha Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun Front Endocrinol (Lausanne) Endocrinology BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944 patients with ASCVD was recruited. Recurrent events occurred during an average of 38.5 months’ follow-up were collected. The respective and combinative roles of major ASCVD (mASCVD) events and high-risk conditions, being defined by 2018 AHA/ACC guideline, in coronary severity and outcome were studied. RESULTS: The number of high-risk conditions was increased with increasing number of mASCVD events (1.95 ± 1.08 vs. 2.16 ± 1.10 vs. 2.42 ± 1.22). Trends toward the higher to the highest frequency of multi-vessel coronary lesions were found in patients with 1- (71.1%) or ≥2 mASCVD events (82.8%) when compared to those without (67.9%) and in patients with 2- (70.5%) or ≥3 high-risk conditions (77.4%) when compared to those with 0-1 high-risk condition (61.9%). The survival rate was decreased by 6.2% between none- and ≥2 mASCVD events or by 3.5% between 0-1 and ≥3 high-risk conditions. Interestingly, diabetes was independently associated with outcome in patients with 1- [1.54(1.06-2.24)] and ≥2 mASCVD events [1.71(1.03-2.84)]. The positive predictive values were increased among groups with number of mASCVD event increasing (1.10 vs. 1.54 vs. 1.71). CONCLUSION: Propitious refinement of ASCVD might be reasonable to improve the survival. Concomitant diabetes was differently associated with the incremental risk among different ASCVD categories, suggesting the need of an appropriate estimate rather than a ‘blanket’ approach in risk stratification. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9096217/ /pubmed/35574011 http://dx.doi.org/10.3389/fendo.2022.860698 Text en Copyright © 2022 Li, Liu, Guo, Zhu, Wu, Xu, Dong, Qian, Dou and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Li, Sha
Liu, Hui-Hui
Guo, Yuan-Lin
Zhu, Cheng-Gang
Wu, Na-Qiong
Xu, Rui-Xia
Dong, Qian
Qian, Jie
Dou, Ke-Fei
Li, Jian-Jun
Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title_full Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title_fullStr Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title_full_unstemmed Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title_short Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
title_sort current guideline risk stratification and cardiovascular outcomes in chinese patients suffered from atherosclerotic cardiovascular disease
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096217/
https://www.ncbi.nlm.nih.gov/pubmed/35574011
http://dx.doi.org/10.3389/fendo.2022.860698
work_keys_str_mv AT lisha currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT liuhuihui currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT guoyuanlin currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT zhuchenggang currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT wunaqiong currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT xuruixia currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT dongqian currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT qianjie currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT doukefei currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease
AT lijianjun currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease